Table 3 Subgroup analysis—shown as forest plot. Adjusted analysis with interaction term
Paracetamol | Control | aOR (95% CI) | Interaction P | Metoclopramide | Control | aOR (95% CI) | Interaction P | Ceftriaxone | Control | aOR (95% CI) | Interaction P | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age | + | + | + | |||||||||
Age < 75 years | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Age > 75 years | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Sex | + | + | + | |||||||||
Male | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Female | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Stroke type | + | + | + | |||||||||
Ischaemic stroke | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Intracerebral haemorrhage | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Other diagnosis | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Stroke severity | + | + | + | |||||||||
NIHSS 6–12 | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
NIHSS > 12 | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Diabetes mellitus | + | + | + | |||||||||
Yes | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
No | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Atrial fibrillation | + | + | + | |||||||||
Yes | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
No | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Pre-stroke mRS | + | + | + | |||||||||
0 | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
> 0 | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Treatment with alteplase | + | + | + | |||||||||
Yes | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
No | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Thrombectomy | + | + | + | |||||||||
Yes | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
No | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Time to treatment | + | + | + | |||||||||
< 6 h | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
6–12 h | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
12–24 h | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | |||
Treatment allocation to other treatment strata | + | + | + | |||||||||
Paracetamol | – | – | – | – | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | ||
Metoclopramide | n/N (%) | n/N (%) | aOR (95% CI) | – | – | – | – | n/N (%) | n/N (%) | aOR (95% CI) | ||
Ceftriaxone | n/N (%) | n/N (%) | aOR (95% CI) | n/N (%) | n/N (%) | aOR (95% CI) | – | – | – | – |